Cobicistat - CAS 1004316-88-4
Catalog number:
B0084-456314
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
COA:
Inquire
Targets:
Cytochrome P450
Description:
Cobicistat is a potent inhibitor of cytochrome P450 3A enzymes, including the important CYP3A4 subtype. It also inhibits intestinal transport proteins, increasing the overall absorption of several HIV medications, including atazanavir, darunavir and tenofovir alafenamide fumarate.
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-456314 25 mg $298 In stock
Bulk Inquiry
Publictions citing BOC Sciences Products
  • >> More
Purity:
0.99
Appearance:
off-white solid
Synonyms:
Cobicistat, GS-9350
MSDS:
Inquire
1.Population pharmacokinetic analysis of elvitegravir and cobicistat in HIV-1-infected individuals.
Barceló C1, Gaspar F2, Aouri M1, Panchaud A2, Rotger M3, Guidi M4, Cavassini M5, Buclin T1, Decosterd LA6, Csajka C7; Swiss HIV Cohort Study. J Antimicrob Chemother. 2016 Mar 29. pii: dkw050. [Epub ahead of print]
OBJECTIVES: Co-formulated elvitegravir, cobicistat, tenofovir disoproxil fumarate and emtricitabine is among the preferred regimens for first-line ART. A population approach was used to characterize the pharmacokinetics of elvitegravir and cobicistat and identify individual factors and co-medications influencing their disposition, taking into consideration the interaction between the two compounds.
2.Evaluating the role of atazanavir/cobicistat and darunavir/cobicistat fixed-dose combinations for the treatment of HIV-1 infection.
Crutchley RD1, Guduru RC2, Cheng AM1. HIV AIDS (Auckl). 2016 Mar 9;8:47-65. doi: 10.2147/HIV.S99063. eCollection 2016.
Atazanavir/cobicistat (ATV/c) and darunavir/cobicistat (DRV/c) are newly approved once daily fixed-dose protease inhibitor combinations for the treatment of HIV-1 infection. Studies in healthy volunteers have established bioequivalence between cobicistat and ritonavir as pharmacoenhancers of both atazanavir (ATV) and darunavir (DRV). In addition, two randomized clinical trials (one Phase II and one Phase III noninferiority trial with a 144-week followup period) demonstrated that cobicistat had sustainable and comparable efficacy and safety to ritonavir as a pharmacoenhancer of ATV through 144 weeks of treatment in HIV-1-infected patients. Furthermore, one Phase III, open-label, single-arm, clinical trial reflected virologic and immunologic responses and safety outcomes consistent with prior published data for DRV/ritonavir 800/100 mg once daily, supporting the use of DRV/c 800/150 mg once daily for future treatment of treatment-naïve and -experienced HIV-1-infected patients with no DRV resistance-associated mutations.
3.Cobicistat Significantly Increases Tacrolimus Serum Concentrations in a Renal Transplant Recipient with Human Immunodeficiency Virus Infection.
Han Z1, Kane BM1, Petty LA2, Josephson MA3, Sutor J4, Pursell KJ2. Pharmacotherapy. 2016 Apr 3. doi: 10.1002/phar.1752. [Epub ahead of print]
Cobicistat is a pharmacokinetic booster in several fixed-dose combination products for treatment of human immunodeficiency virus (HIV) infection. As a potent inhibitor of cytochrome P450 (CYP) 3A enzymes, significant drug-drug interactions are expected between cobicistat and medications that are metabolized primarily through the CYP3A pathway, including calcineurin inhibitors (e.g., tacrolimus and cyclosporine). We describe a case of tacrolimus toxicity due to supratherapeutic tacrolimus concentrations when Stribild® (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) was initiated for newly diagnosed HIV infection in a 50-year-old renal transplant recipient who was previously receiving a stable tacrolimus regimen. Drug-drug interaction via CYP3A inhibition was acknowledged and weekly labs were ordered to allow for close monitoring of renal function and tacrolimus serum concentrations as recommended by Stribild® prescribing information.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Cytochrome P450 Products


CAS 154229-18-2 Abiraterone Acetate

Abiraterone Acetate
(CAS: 154229-18-2)

The acetate form of abiraterone, which blocks the synthesis of androgens by inhibiting CYP17A1.

CAS 755013-59-3 Veledimex racemate

Veledimex racemate
(CAS: 755013-59-3)

Veledimex racemate is the racemate of veledimex. Veledimex is an orally active small molecule diacylhydrazine and controls the expression of the target gene.

CAS 10236-47-2 Naringin

Naringin
(CAS: 10236-47-2)

Naringin inhibits hepatic P-glycoprotein (P-gp) and some drug-metabolizing cytochrome P450 enzymes, including CYP3A4 and CYP1A2, which may result in drug-drug i...

CAS 154229-19-3 Abiraterone

Abiraterone
(CAS: 154229-19-3)

Abiraterone blocks the synthesis of androgens by inhibiting CYP17A1. It is used to treat metastatic, castration-resistant prostate cancer.

CAS 95-25-0 Chlorzoxazone

Chlorzoxazone
(CAS: 95-25-0)

Chlorzoxazone is a muscle-relaxing drug, and a probe for human liver cytochrome P-450IIE1.

CAS 115575-11-6 Liarozole

Liarozole
(CAS: 115575-11-6)

This active molecular has a potential antineoplastic activity. As a retinoic acid metabolism blocking agent (RAMBA), liarozole inhibits P450-dependent ATRA-4-hy...

VT-464 R enantiomer
(CAS: 1375603-38-5)

The R-enantiomer form of VT-464, a non-steroidal compound, has been found to lead to the reduction of androgen through acting as a human CYP17 lyase inhibitor.

UK 39671
(CAS: 85473-17-2)

UK 39671 is a cytochrome P-450 inhibitor

BMS-351
(CAS: 1370001-71-0)

BMS-351 is a selective and nonsteroidal CYP17A1 lyase inhibitor with good selectivity over steroidogenic CYPs 21A2 and 11B1. BMS-351 has become a preclinical ca...

CAS 298-81-7 Methoxsalen

Methoxsalen
(CAS: 298-81-7)

Methoxsalen — also called xanthotoxin, marketed under the trade names Oxsoralen, Deltasoralen, Meladinine — is a drug used to treat psoriasis, eczema, vitiligo,...

CAS 566939-85-3 Orteronel

Orteronel
(CAS: 566939-85-3)

Orterone (TAK-700) is an orally bioavailable non-steroidal androgen synthesis inhibitor of steroid 17alpha-monooxygenase (17,20 lyase) with potential antiandrog...

CAS 851983-85-2 Galeterone

Galeterone
(CAS: 851983-85-2)

Galeterone (TOK-001 or VN/124-1) is a novel antiandrogen under development by Tokai Pharmaceuticals for the treatment of prostate cancer. It possesses a unique ...

VT-1161
(CAS: 1340593-59-0)

VT-1161 is a 14-alpha demethylase inhibitor as a tetrazole antifungal agent originated by Viamet Pharmaceuticals. VT-1161 shows potent efficacy in treatment of ...

CAS 62-68-0 Proadifen Hydrochloride

Proadifen Hydrochloride
(CAS: 62-68-0)

Proadifen hydrochloride is a Cytochrome P450 inhibitor (IC50 = 19μM) and stimulate endothelial cell prostacyclin production.

CAS 50-52-2 Thioridazine

Thioridazine
(CAS: 50-52-2)

Thioridazine is an inhibitor of CYP1A2 and CYP3A2. It is a piperidine typical antipsychotic drug belonging to the phenothiazine drug group and was previously wi...

CAS 54-36-4 Metyrapone

Metyrapone
(CAS: 54-36-4)

Metyrapone acts as a glucocorticoid synthesis inhibitor, blocks cortisol synthesis by inhibiting steroid 11β-hydroxylase in adrenal cortex (IC50 = 7.8 μM).

VT-464
(CAS: 1610537-15-9)

VT-464, also called as Seviteronel, is an oral, non-steroidal, lyase-selective CYP17 inhibitor to reach Phase II clinical trials in Breast cancer in USA (PO). i...

VT-464 racemate
(CAS: 1375603-36-3)

The racemate form of VT-464, a non-steroidal compound, has been found to lead to the reduction of androgen through acting as a human CYP17 lyase inhibitor. IC50...

Dafadine-A
(CAS: 1065506-69-5)

Dafadine-A, the first identified chemical inhibitor of DAF-9, could restrain the dauer formation, developmental timing and longevity in the nematodeCaenorhabdit...

CAS 56-54-2 Conquinine

Conquinine
(CAS: 56-54-2)

Conquinine is a Cytochrome P450 2D6 inhibitor. It is a dextrorotatory stereoisomer of quinine extracted from the bark of the Cinchona tree and similar plant spe...

Chemical Structure

CAS 1004316-88-4 Cobicistat

Quick Inquiry

Verification code

Featured Items